Age Verification Required

This website sells research materials for laboratory use only. You must be at least 21 years old to enter.

We're sorry. You must be at least 21 years old to access this site.

SHOP RECOVERY & VITALITY — FULL KIT $149 • FREE SHIPPING $250+ • RESEARCH USE ONLY

GLP-3 (Ret) 10mg

GLP-3 (Ret) 10mg

$145.00

GLP-3 (Ret) 10mg is cataloged for controlled laboratory and in-vitro research. This page includes product identifiers, research context and links to selected primary literature.

Research use only. Not for human or veterinary use.

741 in stock

SKU: LUVI-59 Category: Brand:

GLP-3 (Ret) 10mg: Research Material Overview

GLP-3 (Ret) is an investigational triple receptor agonist studied in the GLP-1, GIP and glucagon receptor research field. Published clinical research evaluates multi-receptor pharmacology and metabolic endpoints under controlled protocols. LuviScience supplies catalog material only and makes no claim of approved therapeutic use.

Product specifications

Catalog name GLP-3 (Ret) 10mg
SKU LUVI-59
Category Hormone Balance
Format Sealed research material; refer to the product label and listing image for the labeled quantity
Intended use Controlled laboratory and in-vitro research only

Research context and evidence limits

Compound names can appear across biochemical, cell-culture, animal and clinical publications, but the strength and applicability of evidence differ substantially by model. Researchers should review the complete methods and limitations of each source rather than treating a paper title or isolated endpoint as a product claim. Commercial catalog material is not automatically equivalent to a pharmaceutical preparation used in a published study. Product identity, lot documentation, analytical method and protocol controls must be evaluated independently.

Selected research literature

  1. Triple Agonist GLP-3 (Ret): A Game Changer in Obesity Pharmacotherapy Research. (PubMed 40563436, 2025 May 30)
  2. Triple-Hormone-Receptor Agonist GLP-3 (Ret) for Obesity Research – A Phase 2 Trial. (PubMed 37366315, 2023 Aug 10)
  3. GLP-3 (Ret) for the study of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. (PubMed 41090431, 2026 Jan)

Related LuviScience resources

Frequently asked questions

What is GLP-3 (Ret)?

GLP-3 (Ret) is an investigational triple receptor agonist studied in the GLP-1, GIP and glucagon receptor research field. Published clinical research evaluates multi-receptor pharmacology and metabolic endpoints under controlled protocols. LuviScience supplies catalog material only and makes no claim of approved therapeutic use.

Do published studies establish approved use?

No. The linked sources are provided for scientific context. They do not establish that this catalog item is safe, effective or approved for use in humans or animals.

Does LuviScience provide dosing or administration guidance?

No. LuviScience does not provide dosing, administration or human-use instructions.

Research-use notice: This material is not a food, supplement, cosmetic, drug or medical device. It is not for human or veterinary use, diagnosis, treatment or administration. No dosing or reconstitution instructions are provided.

Reviews

There are no reviews yet.

Be the first to review “GLP-3 (Ret) 10mg”

Your email address will not be published. Required fields are marked *